Sapre Nikhil, Selth Luke A
Department of Surgery, Royal Melbourne Hospital, The University of Melbourne, Level 5 Clinical Sciences Building, Parkville, Melbourne, VIC 3050, Australia.
Prostate Cancer. 2013;2013:539680. doi: 10.1155/2013/539680. Epub 2013 Mar 12.
MicroRNAs are key regulators of gene expression and play critical roles in both normal physiology and pathology. Recent research has demonstrated that these molecules are present in body fluids, such as serum, plasma, and urine, and can be readily measured using a variety of techniques. More importantly, emerging evidence suggests that circulating or urine miRNAs are useful indicators of disease. Here, we consider the potential utility of such miRNAs as noninvasive biomarkers of prostate cancer, a disease that would benefit substantially from novel diagnostic and prognostic tools. The studies aimed at identifying diagnostic, prognostic, and/or predictive miRNAs for prostate cancer are summarised and reviewed. Finally, practical considerations that will influence the translation of this recent research into clinical implementation are discussed.
微小RNA是基因表达的关键调节因子,在正常生理和病理过程中均发挥着关键作用。最近的研究表明,这些分子存在于血清、血浆和尿液等体液中,并且可以使用多种技术轻松进行测量。更重要的是,新出现的证据表明,循环或尿液中的微小RNA是疾病的有用指标。在此,我们探讨了此类微小RNA作为前列腺癌非侵入性生物标志物的潜在用途,前列腺癌这一疾病将从新型诊断和预后工具中大幅受益。总结并综述了旨在鉴定前列腺癌诊断、预后和/或预测性微小RNA的研究。最后,讨论了将这项最新研究转化为临床应用时会涉及的实际考量。